Results 171 to 180 of about 5,547 (244)

Ensuring Sustainability in Pharmaceutical Care: A Retrospective Analysis of Administrative Databases on the Utilization, Costs, and Switching Patterns of Biological Therapies in the Agency for Health Protection of the Metropolitan Area of Milan. [PDF]

Pharmaceuticals (Basel)
Langfelder RMB, Langella R, D'Angelo C, Panico C, Cattaneo S.   +4 more
europepmc   +1 more source

Development of Biosimilar Aflibercept SDZ-AFL. [PDF]

Curr Ther Res Clin Exp
Dodeller F, Alliger P, Heyn J, Urosevic D, Allmannsberger L, Wersig C, Silva R.   +6 more
europepmc   +1 more source

Biosimilars and implications for pharmacy practice: Ready or not, here they come!

Pharmacy Practice, 2019
Hobbs AL, Crawford JP
doaj   +1 more source

Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.

JAMA Netw Open
Abdelaziz A, Winn AN, Dusetzina SB, Mitchell AP.   +3 more
europepmc   +1 more source

Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration. [PDF]

BMJ Open Ophthalmol
Balser S, Capsius B, Hole R, Papp A, Preissinger N, Rozenknop A, Tiko T.   +6 more
europepmc   +1 more source

Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial. [PDF]

Cardiovasc Diabetol Endocrinol Rep
Ghosh S, Sethi B, Kalra S, Baruah MP, Mane A, Choudhari S, Petare A, Jadhav M, Patil S, Barkate H.   +9 more
europepmc   +1 more source

Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study. [PDF]

BioDrugs
Schiestl M, Roy N, Trieb M, Park JP, Guillen E, Woollett G, Wolff-Holz E.   +6 more
europepmc   +1 more source

Pharmaceutical Patents, Paragraph IV, and Pay-for-Delay: The Landscape of Drung Patent Litigation and the Lessons Provided for the Recently Passed Biosimilar Approval Pathway

, 2010
Brett Havranek
openalex   +1 more source

Knowledge, Attitudes, and Practices Regarding Biosimilars Among Pharmacists and Physicians in Saudi Arabia: A Scoping Review. [PDF]

Cureus
Alanizi A, Alotaibi R, Babalghaith R, Alzahrani A, Qubaiban R, Hattan A, Alnuhait M, Al Sharif A.   +7 more
europepmc   +1 more source

Antitrust and the Biopharmaceutical Industry: Lessons from Hatch-Waxman and an Early Evaluation of the Biologics Price Competition and Innovation Act of 2009 [PDF]

, 2010
Seamon, Matthew J
core   +1 more source